Employers Are Steering Workers Toward Controversial Stem Cell Therapies
A Midwestern grocery chain, Hy-Vee, is taking an unusual—and highly controversial—approach to reducing health care costs. Before employees in certain cities can undergo knee replacement, they first must visit a stem cell provider. Hy-Vee has contracted with one of the U.S.’ leading stem cell companies—Regenexx, based in Des Moines, Iowa—that claims injections of concentrated bone marrow or platelets can help patients avoid expensive joint surgery. Regenexx has persuaded over 100 employers to include its services in their health insurance plans. In a marketing booklet, Regenexx, whose injections range in price from $1,500 to $9,000, notes that its treatments cost a fraction of major surgery. A single knee replacement, for example, ranges from $19,000 to $30,000 in the U.S. The benefits of stem cells are hotly debated in the medical community, and federal regulators have warned the public to beware of clinics that peddle unapproved injections as a cure-all. Many doctors and ethicists say they fear the public is being misled about how well stem cells work—and whether the procedures save their money or waste it. “This definitely is not a high-quality, proven treatment,” says Dr. Freddie Fu, chairman of orthopedic surgery at the University of Pittsburgh Medical Center. Knee Pain and the Bottom Line Health insurance typically doesn’t cover stem cell injections, with the exception of certain accepted treatments, such as bone-mar...
ConclusionElevated AURKB expression was strongly correlated to TMZ resistant acquisition and poor prognosis, furthermore, targeting AURKB would be a potential therapeutic target for GBM patients.
The objective of this article is to document whether DIRT can accurately map the position of the perforators and measure their influence on the perfusion of the flap in order to select the best perforators to improve the outcome of breast reconstructions with free DIEP flaps. A systematic review of the literature published between January 1998 and November 23th 2018 was conducted regarding the possible benefit of dynamic infrared thermography (DIRT) in DIEP-flap breast reconstructions.The databases PubMed and Web of Science were used to search for qualified articles. Inclusion criteria were women who underwent a breast rec...
ConclusionsIn this pilot study we observed a consistent and statistically significant decrease in VI and fibroid volume after three months of LPA treatment in patients with uterine fibroids. The decrease in fibroid volume and VI was less consistent after UPA use. The strong correlation between the VI at baseline and volume reduction, may in theory be used to predict the volume reduction after LPA.
Publication date: Available online 23 August 2019Source: European Journal of Obstetrics &Gynecology and Reproductive BiologyAuthor(s): Susie Brousse, Marine Joste, Franck Marie Leclère, Vincent Lavoué, Nicolas Bertheuil
This study aimed to describe the prevalence of FID in patients with CKD on HD, characterize the included individuals in terms of clinical and workup parameters, and assess their nutritional, oxidative stress, and inflammation statuses. This cross-sectional study assembled a convenience sample of 183 patients with CKD on HD treated in Southern Brazil. Patients meeting the inclusion and exclusion criteria were divided into two groups, one with anemic subjects with FID and one with anemic patients without FID. Participants answered a questionnaire probing into socio-epidemiological factors, underwent anthropometric measuremen...
One woman's truly life-changing experience of caring for a mother with cancer.
Two studies explore outcomes for low-income, middle-aged adults.
No abstract available
Alpelisib (Piqray) is now approved to treat postmenopausal women or men who have hormone receptor–positive, human epidermal growth factor receptor 2–negative, PIK3CA-mutated, advanced or metastatic breast cancer that has progressed during or after endocrine-based therapy.
Conclusions: No safety concerns were identified from this retrospective EHR review of hospitalized adults who received a milk and molasses enema for constipation relief. The findings indicate that this treatment is safe, although further study examining its efficacy in this population is needed.
More News: Anemia | Aplastic Anemia | Arthritis | Australia Health | Back Pain | Bone Marrow Transplant | Canada Health | Cancer | Cancer & Oncology | Children | Chronic Pain | Contracts | Food and Drug Administration (FDA) | Gastroschisis Repair | Government | Health | Health Insurance | Health Management | Insurance | Insurers | Jobs | Learning | Legislation | Marketing | Medical Ethics | Medical Law | Medical Tourism | Orthopaedics | Pain | Physical Therapy | Rheumatology | Sodium Chloride | Sports Medicine | Stem Cell Therapy | Stem Cells | Study | Transplants | Ultrasound | Universities & Medical Training | University of Minnesota | Websites | Weight Loss